- |||||||||| Tembexa (brincidofovir oral) / SymBio Pharma, Vistide (cidofovir) / Gilead, TPOXX (tecovirimat) / SIGA Technologies
Review, Journal: Mini Review on Clinical Aspects of Monkeypox. (Pubmed Central) - Sep 15, 2023
For the prevention of monkeypox, the Center for Disease Control and Prevention recommends the administration of the same vaccine used for smallpox named INVAMUNE, which is currently in its third generation. Its first and second generations have adverse side effects in patients having HIV or atopic dermatitis.
- |||||||||| JYNNEOS (live modified vaccinia virus ankara) / Bavarian Nordic, TPOXX (tecovirimat) / SIGA Technologies
Review, Journal: Update on Mpox: a brief narrative review. (Pubmed Central) - Sep 13, 2023
Tecovirimat is the drug of choice for treating severe cases although there is no evidence of efficacy from randomised controlled trials. Immunization with a live non-replicating vaccine (JYNNEOS) effectively reduces the disease's incidence.
- |||||||||| Vistide (cidofovir) / Gilead, TPOXX (tecovirimat) / SIGA Technologies
Monkeypox across countries from Central and Eastern Europe (ETIUDA) - Sep 10, 2023 - Abstract #EACS2023EACS_274;
The number of mpox skin lesions was increased in severely immunosuppressed PLWH, predominantly in the genital area. Effective contact tracing and vaccination are important strategic pillars to control mpox outbreaks.
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Journal: A 40-Year-Old Man with Anemia, Proctitis, Rectal Bleeding, and a Perianal Rash Due to Mpox (Monkeypox) Infection. (Pubmed Central) - Sep 7, 2023
On initial presentation, swabbing of the lesions and polymerase chain reaction (PCR) testing confirmed a diagnosis of mpox infection, and treatment with a 14-day course of Tecovirimat was started...CONCLUSIONS Despite treatment with antiviral agents, mpox infection can progress quickly; thus, swift management with a multidisciplinary approach and close follow-up is needed to treat and prevent secondary complications such as anemia and proctitis. Further data collection regarding the sexual practices of those with diagnoses of mpox as well as seminal, anorectal, and genital swabbing would be valuable to confirm the mode of transmission and cause of mpox proctitis.
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Journal: Implementation and early outcomes of a telehealth visit model to deliver tecovirimat for mpox infection in New York City. (Pubmed Central) - Aug 26, 2023
We observed favorable treatment outcomes, with no serious adverse events, hospitalizations, or deaths related to mpox. While equitable access to telehealth remains a limitation that needs to be addressed, this telehealth model enabled a rapid scale-up of tecovirimat prescription during the mpox outbreak, and should be considered as an important tool used to respond to future infectious disease outbreaks.
- |||||||||| Tembexa (brincidofovir oral) / SymBio Pharma, TPOXX (tecovirimat) / SIGA Technologies
Journal: Identification of IMP Dehydrogenase as a Potential Target for Anti-Mpox Virus Agents. (Pubmed Central) - Aug 21, 2023
To identify drug targets for the development of anti-MPXV agents, we screened a chemical library using an MPXV infection cell assay and found that gemcitabine, trifluridine, and mycophenolic acid (MPA) inhibited MPXV propagation...Although brincidofovir and tecovirimat are drugs approved for the treatment of smallpox by the U.S. Food and Drug Administration, their efficacy against mpox has not been established...We also suggested IMP dehydrogenase as a potential target for the development of anti-mpox virus agents. By targeting this molecule, we identified a series of compounds with stronger anti-mpox virus activity than mycophenolic acid.
- |||||||||| Tembexa (brincidofovir oral) / SymBio Pharma, brequinar (DUP 785) / BMS, Clear Creek Bio, TPOXX (tecovirimat) / SIGA Technologies
Preclinical, Journal: Identification of In Vitro Inhibitors of Monkeypox Replication. (Pubmed Central) - Aug 21, 2023
The supply of MPXV vaccines is limited, and only two antivirals, tecovirimat and brincidofovir, approved by the U.S. Food and Drug Administration (FDA) for the treatment of smallpox, are currently available for the treatment of MPXV infection...Seven compounds from the ReFRAME library (antimycin A, mycophenolic acid, AVN-944, pyrazofurin, mycophenolate mofetil, azaribine, and brequinar) and six compounds from the NPC library (buparvaquone, valinomycin, narasin, monensin, rotenone, and mubritinib) showed inhibitory activity against rVACV...Here, we show that 13 compounds, derived from two different libraries, previously found to inhibit several RNA viruses, also inhibit VACV. Notably, 11 compounds also displayed inhibitory activity against MPXV.
- |||||||||| Review, Journal: Emerging pharmacological strategies for treating and preventing mpox. (Pubmed Central) - Aug 18, 2023
Tecovirimat has emerged as a safe frontline treatment for mpox, while brincidofovir use has been limited by safety concerns. VIGIV and cidofovir should be reserved for the most severe cases in which other options are not fully effective.
- |||||||||| Review, Journal: Human monkeypox: history, presentations, transmission, epidemiology, diagnosis, treatment, and prevention. (Pubmed Central) - Aug 7, 2023
Several vaccines have already been developed (e.g., JYNNEOS, ACAM2000 and ACAM3000) and antiviral drugs (e.g., cidofovir and tecovirimat) can also be used to treat the disease. In the present study, we reviewed the history, morphology, clinical presentations, transmission routes, diagnosis, prevention, and potential treatment strategies for monkeypox, in order to enable health authorities and physicians to better deal with this emerging crisis.
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Review, Journal: Mpox and HIV: a Narrative Review. (Pubmed Central) - Aug 7, 2023
Supportive, symptomatic care and single or combination mpox-directed antiviral drugs are commonly used in PWH with severe mpox disease. Data from randomized clinical control trials on the efficacy of therapeutic and preventive tools against mpox among PWH are needed to better guide clinical decisions.
- |||||||||| Review, Journal: Clinical Strategies and Therapeutics for Human Monkeypox Virus: A Revised Perspective on Recent Outbreaks. (Pubmed Central) - Aug 2, 2023
In the line of expanded MPXV prevalence, we further reviewed its clinical management and the diverse employed preventive/therapeutic strategies, including vaccines (JYNNEOS, ACAM2000, VIGIV) and antiviral drugs/inhibitors (Tecovirimat, Cidofovir, Brincidofovir). Taken together, with a revised perspective of HMPX re-emergence, the present report summarizes new knowledge on its prevalence, pathology, and prevention strategies.
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Acute Proctitis in a Patient With Mpox and Syphilis (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_3603;
Prompt identification as well as a high index of suspicion are necessary for proper diagnosis and management of monkeypox and syphilis in immunocompromised patients with acute proctitis. Figure: CT scan of the pelvis
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
A Case of Mpox Proctitis in an HIV-Positive Transgender Female (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_3586;
Monkeypox PCR returned positive, and the patient responded well to treatment with tecovirimat...This case highlights the importance of recognizing and managing the unusual presentations of monkeypox in immunocompromised patients, including proctitis and rectal perforation. Figure: Rash between anal folds with yellow discharge (A) and vesciular rash on lower extremities (B)
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Unmasking the Hidden: Mpox-Induced Proctocolitis (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_2146;
The patient was stabilized and discharged on oral Tecovirimat (TPOXX) 600 mg twice daily for 14 days...This case underscores the importance of prompt medical attention and clinical suspicion, emphasizing clinicians' responsibility to educate patients on Monkeypox's clinical manifestations and prevention to ensure a timely and accurate diagnosis. Figure: Captions are mentioned in the Figure.
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Perianal Mpox Infection in a Patient Without Risk Factors or Exposure (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_2113;
The patient did not meet criteria for treatment with Tecovirimat at the time of presentation and was subsequently discharged after improvement in pain...Figure 2: Perianal ulcerations. Figure 3: Normal rectum.
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Mpox Virus-Associated Severe Proctitis in a Young Male (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_787;
A 2-week course of tecovirimat was started and the patient was discharged into isolation...Thus, mpox should be suspected in MSM presenting with proctitis, even if no other lesions are found. Figure: CT scan demonstrating significant circumferential wall thickening of the rectum, suggestive of severe proctitis
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Severe Mpox Proctitis in an HIV Patient with Normal CD4 Count (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_747;
After no significant improvement in symptoms, Tecovirimat was initiated...This case emphasized that patients with a CD4 count > 500 are still at risk for developing severe proctitis and that Mpox should be added to differential diagnosis for all patients presenting with proctitis, especially in the setting of the current outbreak. Figure: Image 1 and 2 show different stages of the rash and Image 3 shows severe proctitis on the CT
- |||||||||| Review, Journal: Mpox: Rapid Evidence Review. (Pubmed Central) - Jul 17, 2023
Possible complications of mpox include anogenital pain, bacterial superinfections of skin lesions, dehydration secondary to oral lesions, encephalitis, keratitis, and respiratory distress. To date, 38 deaths have been reported in the United States.
- |||||||||| Journal: Potential therapeutic targets for Mpox: the evidence to date. (Pubmed Central) - Jul 17, 2023
The WHO also included cidofovir, NIOCH-14, and other vaccines as treatment options...However, conserved resistance mutation positions in MPXV and related poxviruses, and the signature mutations in the 2022 MPXV can potentially compromise the efficacy of the EUA-granted treatments. Therefore, MPXV-specific medications are required not only for the current but also for possible future outbreaks.
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Journal: [[Translated article]]RF - Potential Treatments for Monkeypox. (Pubmed Central) - Jul 12, 2023
Our results support screening different MPXV isolates for tecovirimat susceptibility as an important tool to better use of the restricted number of tecovirimat doses available in low-income countries to treat patients with mpox. No abstract available
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Journal: Characteristics of Mpox Infections in Louisiana in the 2022 Outbreak. (Pubmed Central) - Jul 10, 2023
We abstracted data on HIV status, immune function (CD4 count, viral load), anti-retroviral therapy regimen, symptoms and severity of infection, vaccinations status, and whether tecovirimat was administered...The demographic data from Louisiana, a state with high prevalence of STIs and HIV/AIDS, are consistent with prior reports describing the 2022 Mpox outbreak. Our results contribute to accumulating data on the severity of infection in individuals with HIV-related immunocompromise.
- |||||||||| JYNNEOS (live modified vaccinia virus ankara) / Bavarian Nordic, TPOXX (tecovirimat) / SIGA Technologies
Journal: Structure of monkeypox virus poxin: implications for drug design. (Pubmed Central) - Jul 2, 2023
Despite the availability of an FDA-approved vaccine (JYNNEOS) and an effective drug (tecovirimat), concerns remain over the possible recurrence of a viral pandemic...The structure reveals a conserved, predominantly ?-sheet fold and highlights the high conservation of the cGAMP binding site and of the catalytic residues His17, Tyr138, and Lys142. This research suggests that poxin inhibitors could be effective against multiple poxviruses.
|
